Please ensure Javascript is enabled for purposes of website accessibility

Will These Numbers from Pfizer Be Good Enough for You?

By Seth Jayson - Updated Apr 7, 2017 at 12:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Checking expectations

Pfizer (NYSE: PFE) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will wither -14.6% and EPS will wither -16.1%.

The average estimate for revenue is $14.68 billion. On the bottom line, the average EPS estimate is $0.52.

Revenue details
Last quarter, Pfizer recorded revenue of $15.06 billion. GAAP reported sales were 8.7% lower than the prior-year quarter's $16.49 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.62. GAAP EPS of $0.43 for Q2 were 30% higher than the prior-year quarter's $0.33 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 82.1%, 50 basis points better than the prior-year quarter. Operating margin was 36.4%, 470 basis points better than the prior-year quarter. Net margin was 21.6%, 580 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $59.55 billion. The average EPS estimate is $2.21.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,463 members out of 6,055 rating the stock outperform, and 592 members rating it underperform. Among 1,559 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,460 give Pfizer a green thumbs-up, and 99 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.92.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.47 (3.59%) $1.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.